What type of pharmaceutical dosage form does spaxentan/sparsentan belong to?

Sparsentan/Sparsentan is an oral drug that is a dual receptor antagonist. It mainly works by simultaneously antagonizing angiotensin II receptors (AT1 receptors) and endothelin A receptors (ETA receptors) to achieve therapeutic effects. The mechanism of action of sparsentan combines the advantages of two classic drugs: it has antihypertensive effects and can slow down the progression of kidney disease by improving kidney function. Therefore, it has been widely studied and used in the treatment of kidney disease.

Sparsentan is available as oral tablets, usually supplied to patients in 100mg or 200mg sizes. The drug is designed in tablet form that is easy for patients to take, and patients take it once a day as recommended by their doctor, usually after a meal to improve the absorption and efficacy of the drug. Unlike many traditional drug treatments, sparsentan, as a dual receptor antagonist, reduces the vascular burden on the kidneys and improves kidney function by precisely regulating the mechanism of vasoconstriction and dilation, and is especially suitable for the management of chronic kidney disease.

Because sparsentan works through dual mechanisms in the body, it can not only reduce the contraction of renal blood vessels through its anti-angiotensinII effect, but also reduce renal fibrosis through its anti-endothelin effect, thereby slowing down the progression of kidney disease. This mechanism makes it a potential emerging therapy in the treatment of chronic kidney disease, especially IgA nephropathy and tubulointerstitial disease.

Overall, sparsentan has great potential in the treatment of primary immunoglobulin A nephropathy (IgAN), especially in reducing proteinuria, slowing kidney damage and improving patients' overall kidney function. However, patients should still follow their doctor's instructions when using this drug and conduct regular renal function monitoring and evaluation to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.sparsentan.com/